Breast cancer VPAC1 receptors.
VIP receptors were investigated in breast cancer biopsy specimens. Twenty biopsy specimens bound 125I-VIP with high affinity. Also, each of the 20 biopsy specimens had high amounts of VPAC1 receptor mRNA. MCF-7 cells have VPAC1 receptors that bound the VIP chemotherapeutic conjugate, (Ala2,8,9,19,24,25,27 Nle17, Lys28)VIP-L2-camptothecin, with high affinity. VIP chemotherapeutic conjugates may be useful agents to inhibit the growth of breast cancer.
Moody
Terry W
TW
Department of Health and Human Services, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. moodyt@mail.nih.gov
Jensen
Robert T
RT
D001706:Biopsy; D001943:Breast Neoplasms / Q000145:classification / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D006801:Humans; D051238:Receptors, Vasoactive Intestinal Polypeptide, Type I / Q000235:genetics / Q000378:metabolism*
D051238:Receptors, Vasoactive Intestinal Polypeptide, Type I